Literature DB >> 33827125

Cardiovascular Considerations in Anesthetic Management for a Patient With Antiphospholipid Syndrome and Decreased Cardiac Function: A Case Study.

Makiko Shibuya1, Yukifumi Kimura1, Shigeru Takuma1, Nobuhito Kamekura Dds1, Toshiaki Fujisawa1.   

Abstract

This case report describes the prolonged general anesthetic management of a 41-year-old woman with antiphospholipid syndrome (APS), systemic lupus erythematosus, and previously undiagnosed decreased cardiac function who underwent planned partial resection of the left tongue, tracheostomy, neck dissection, and pedicled flap reconstruction. This was immediately followed by emergent surgery to salvage the flap, and 1 month later, revision of the soft tissue flap was performed. A preoperative echocardiogram was performed because of her various risk factors, which identified lateral wall hypokinesis and reduced left ventricular ejection fraction of 40%, despite no known cardiovascular disease. However, cardiology consult determined no additional treatment was needed before the surgery. Multiple antithrombotic strategies were used, including elastic stockings, intermittent pneumatic compression devises, and heparin bridging. During the general anesthetic, stroke volume variation (SVV) was used to assess cardiac function and guide fluid management. There were no signs of systemic thrombosis, although the free flap reconstruction was abandoned because of a thrombus in the vascular anastomosis. Cardiac function can deteriorate in APS patients because of coronary and/or microvascular thrombosis. Therefore, it is necessary to evaluate cardiac function, regardless of a known history of cardiovascular disease. Moreover, additional monitoring (ie, SVV) may be useful during prolonged general anesthetics for patients with APS and cardiac dysfunction.
© 2021 by the American Dental Society of Anesthesiology.

Entities:  

Keywords:  Antiphospholipid syndrome; Cardiac function; General anesthesia; Stroke volume variation; Thrombosis

Year:  2021        PMID: 33827125      PMCID: PMC8033580          DOI: 10.2344/anpr-67-03-07

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  10 in total

1.  Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study.

Authors:  Karim Sacré; Benoit Brihaye; Fabien Hyafil; Jean-Michel Serfaty; Brigitte Escoubet; Maria-Christina Zennaro; Olivier Lidove; Jean-Pierre Laissy; Thomas Papo
Journal:  Arthritis Rheum       Date:  2010-07

Review 2.  The catastrophic antiphospholipid syndrome.

Authors:  R A Asherson
Journal:  J Rheumatol       Date:  1992-04       Impact factor: 4.666

Review 3.  Lessons from the "Euro-Phospholipid" project.

Authors:  Ricard Cervera
Journal:  Autoimmun Rev       Date:  2007-12-03       Impact factor: 9.754

Review 4.  Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients.

Authors:  R A Asherson; R Cervera; J C Piette; J Font; J T Lie; A Burcoglu; K Lim; F J Muñoz-Rodríguez; R A Levy; F Boué; J Rossert; M Ingelmo
Journal:  Medicine (Baltimore)       Date:  1998-05       Impact factor: 1.889

5.  [Prophylaxis of perioperative pulmonary thromboembolism in a patient with anti-phospholipid antigen syndrome].

Authors:  Yoko Ebina; Yoshihiko Kishi; Mika Baba; Tomoko Kitamura; Takeshi Iritakenishi; Michioki Kuri; Noriko Kanbara; Hironobu Tanigami; Masahiko Higashiyama
Journal:  Masui       Date:  2005-11

6.  Coronary microvasculopathy and intracardiac thrombosis in antiphospholipid syndrome.

Authors:  Razvan Onea; Philippe Germain; André Zimmermann
Journal:  Arch Cardiovasc Dis       Date:  2012-04-13       Impact factor: 2.340

7.  Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome.

Authors:  N Kattwinkel; A G Villanueva; S B Labib; H T Aretz; J W Walek; D L Burns; J T Klenz
Journal:  Ann Intern Med       Date:  1992-06-15       Impact factor: 25.391

8.  Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant.

Authors:  J Nojima; E Suehisa; N Akita; M Toku; R Fushimi; H Tada; H Kuratsune; T Machii; T Kitani; N Amino
Journal:  Br J Haematol       Date:  1997-03       Impact factor: 6.998

9.  Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

Authors:  Ricard Cervera; Jean-Charles Piette; Josep Font; Munther A Khamashta; Yehuda Shoenfeld; María Teresa Camps; Soren Jacobsen; Gabriella Lakos; Angela Tincani; Irene Kontopoulou-Griva; Mauro Galeazzi; Pier Luigi Meroni; Ronald H W M Derksen; Philip G de Groot; Erika Gromnica-Ihle; Marta Baleva; Marta Mosca; Stefano Bombardieri; Frédéric Houssiau; Jean-Christophe Gris; Isabelle Quéré; Eric Hachulla; Carlos Vasconcelos; Beate Roch; Antonio Fernández-Nebro; Marie-Claire Boffa; Graham R V Hughes; Miguel Ingelmo
Journal:  Arthritis Rheum       Date:  2002-04

Review 10.  Antiphospholipid syndrome; its implication in cardiovascular diseases: a review.

Authors:  Ioanna Koniari; Stavros N Siminelakis; Nikolaos G Baikoussis; Georgios Papadopoulos; John Goudevenos; Efstratios Apostolakis
Journal:  J Cardiothorac Surg       Date:  2010-11-03       Impact factor: 1.637

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.